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Abstract
Background Hip fractures require operation within
36–48 h, and they are most common in the elderly. A high
International Normalized Ratio should be corrected before
surgery. In the current study, we analyzed the budget im-
pact of various warfarin reversal approaches.
Methods Four reversal strategies were chosen for the
budget impact analysis: the temporary withholding of
warfarin, administration of vitamin K, fresh frozen plasma
(FFP), and a four-factor prothrombin complex concentrate
(PCC).
Results We estimated that, annually, 410 hip fracture
patients potentially require warfarin reversal in Finland.
The least costly treatment was vitamin K, which accounted
for €289,000 in direct healthcare costs, and the most costly
treatment option was warfarin cessation, which accounted
for €1,157,000. In the budget impact analysis, vitamin K,
PCC and FFP would be cost-saving to healthcare compared
with the current treatment mix.
Conclusion The various warfarin reversal strategies have
different onset times, which may substantially impact the
subsequent healthcare costs.
Key Points
Reversal of anticoagulation is required prior to
surgery. Prevalence of anticoagulation therapy
increases with aging population.
Method of anticoagulation reversal influences
operation delay and medication costs. This should be
taken into account when estimating the overall costs
of treatment strategy options.
Budget impact analyses based on local patient
population demonstrate the cost impact of adopting
alternative treatment options. The method should be
more widely used to support decision making.
1 Introduction
Finland has a population of 5.5 million, and the annual
incidence of a first hip fracture is approximately 6000 [1].
Old age represents a major risk factor, and the incidence
increases 13-fold from 60 to 80 years of age [2]. Although
there is a continuous decreasing trend of age-adjusted in-
cidence of hip fractures, based on the aging population and
increasing life expectancy, the absolute number of hip
fractures is likely to double during the next two decades
[3].
Early surgery for hip fractures is encouraged. Operative
delay beyond 48 h after admission may increase 30-day
mortality by 41 % [4]. The current guidelines promote
surgery during the first 36–48 h after the fracture because
the best available evidence indicates a reduction in mor-
tality, complications, shortening of hospital stay, and
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earlier return to independent living with early compared
with late surgery [5].
Most elderly patients have comorbidities, and patients
must be medically optimized before surgery. In Finland,
12 % of hip fracture patients must wait over 48 h for
surgery [1]. One reason for the extended waiting times is
the use of oral anticoagulants. In Finland, 8–16 % of the
elderly use warfarin [6], and the resulting anticoagulation
should be reversed prior to surgery.
The reversal strategies include the temporary with-
holding of warfarin and the administration of vitamin K,
fresh frozen plasma (FFP), or prothrombin complex con-
centrate (PCC) [7, 8]. The choice of treatment method
depends on the urgency of the anticoagulant effect reversal.
Withholding warfarin is not a feasible method because the
international normalized ratio (INR) may take 3–7 days to
normalize. If 3 mg of intravenous vitamin K is adminis-
tered in addition to withholding warfarin, appropriate he-
mostatic function can be restored within 24 h in most
patients with a therapeutic INR [9]. However, vitamin K
may lack effectiveness in patients with supratherapeutic
INR ratios, and patients should have normal liver function
to synthesize and activate vitamin K-dependent clotting
factors. FFP is a potential treatment of choice for hy-
povolemic patients who do not have anemia. However, a
large infusion volume is required and may not be tolerated
by patients with cardiac, renal, or pulmonary diseases.
Four-factor PCCs contain coagulation factors II, VII, IX,
and X, and proteins C and S. Therefore, they are highly
effective in correcting INR as soon as they are in circula-
tion. PCCs can be administered by short-term infusion
without a risk of volume overload [7].
The four aforementioned reversal strategies have dif-
ferent onset times; therefore, the treatment choice sub-
stantially impacts the surgical operation delay. The budget
impact of these various warfarin reversal approaches has
not been established but should be considered in decision
making. In the present study, we evaluated the costs of
warfarin reversal from the perspective of a hospital in
Finland and then evaluated the budget impact of PCC
compared with the other three reversal strategies.
2 Methods
2.1 Patient Population and Patient Characteristics
In the present study, the incidence of 4418 hip fracture
patients in Finnish hospitals in 2009 was applied based on
the results of the Finnish PERFECT initiative [1]. This
incidence includes community-dwelling patients with a
first hip fracture episode in the past 10 years, patients older
than 50 years, and a defined treatment period in the
surgical unit [1]. The average age of the population was
78.8 years, and the prevalence of men was 31.8 % [1]. The
prevalence of hip fracture patients with warfarin therapy
was estimated according to the Finnish population-based
study of anticoagulant treatment [6]. Based on these data,
we estimated that 8 % of females and 12 % of males in
between the ages of 75 and 79 years received anticoagulant
therapy. In this base-case analysis, the patients were as-
sumed to have an initial INR of 3.0 and bodyweight of
70 kg, which was assumed to reflect the average patient
population. The target INR was assumed to be B1.5.
2.2 Questionnaire-Based Survey of Clinical Practice
in Finland
A questionnaire was mailed to all chief anesthetists
(n = 27) at the secondary and tertiary care hospitals in
Finland. The survey was performed in autumn 2012. The
physicians were provided with a case scenario of a 75-year-
old, community-dwelling patient (weighing 75 kg, INR
3.0, hemoglobin 115 g/L, and hematocrit 0.33) with a hip
fracture who had the last dose of warfarin for atrial fibril-
lation 20 h earlier. The anesthetists were asked to provide
their anesthesia method, warfarin reversal method, and
target INR in a case in which the patient would undergo
surgery within the next 6 h and surgery and intrathecal
anesthesia were contraindicated only because the INR ratio
was 3.0. The respondents were also asked to specify their
method of reversal in normovolemic and hypovolemic
patients. Additionally, the dose regimen and combination
of the reversal therapies (vitamin K, PCC, and FFP) and the
dosage form of vitamin K were asked. The questionnaire
used both multiple-choice and open-ended questions. The
protocol was approved by the Research Ethics Committee
of the Hospital District of Northern Savo, Kuopio, Finland
(no. 60/2012).
2.3 Methods of Anticoagulation Reversal
The following four reversal strategies were chosen for the
analysis (Table 1): the temporary withholding of warfarin,
administration of vitamin K (Konakion Novum, Roche,
Espoo, Finland), FFP (OctaplasLG, Octapharma Nordic,
Stockholm, Sweden), and a four-factor PCC (Cofact,
Sanquin, Amsterdam, the Netherlands). In the current
treatment mix, 50/50 share of two commercial PCC
preparations (PCC1: Cofact, Sanquin, Amsterdam, the
Netherlands and PCC2: Octaplex, Octapharma AG,
Lachen, Switzerland) was assumed. Low molecular weight
heparin (LMWH), enoxaparin sodium was considered as a
bridging therapy during warfarin cessation and vitamin K
treatment. The dose regimens that were applied in the
analysis are presented in Table 1.
156 T. Purmonen et al.
2.4 Resource Use, Drug Costs, and Applied Values
The study included factors that are related to anticoagula-
tion reversal prior to emergency hip surgery during hos-
pitalization in Finland (Table 1). The incremental costs
that are caused by delayed operation include the laboratory
(INR laboratory test) and hospitalization costs prior to
operation. The costs of warfarin reversal were supple-
mented to estimate the total costs of the treated patient
population. All healthcare unit costs were indexed to the
2013 value. The prices of the applied drug products were
Finnish wholesale prices without value added tax (VAT)
and without any discounts. Drug wastage was included in
the medication costs (rounding up to the full packages).
Medication costs under €300/day were omitted to avoid
double counting with hospitalization costs (cost of vitamin
K and enoxaparin sodium were less than €300 and, there-
fore, omitted). Different safety and adverse event profiles
were not taken into account. Each individual treatment
option represented a 100 % treatment share in the analysis.
In the later stage of the analysis, the treatment mix was
estimated according to the survey of clinical practice in
Finnish hospitals. The time range of the analysis was
1 year, including direct healthcare and drug costs that were
related to the hip surgery hospitalization.
The resource use that was related to the various warfarin
reversal methods was estimated according to the current
clinical practice in Kuopio University Hospital. The chosen
method affects the number of hospital days and INR tests
needed during the treatment. The amount of additional
resource use was related to the prolonged follow-up prior
to surgery. In the base-case analysis, a unit cost of €706 for
each hospital day in the traumatology treatment unit was
used. The unit cost of a hospital day included medication
costs that were less than €300/day and INR laboratory tests.
Finally, the cost of PCC treatment was compared with
vitamin K, FFP, and cessation of warfarin therapy, and the
budget impact of each individual treatment option com-
pared with the current treatment mix was estimated.
2.5 Sensitivity Analysis
In the sensitivity analysis, patients were assumed to have
an initial INR of 2.5, 3.0, or 3.5 and a bodyweight of 60,
70, or 80 kg. The target INR was assumed to be B1.5 in all
scenarios. In addition, the unit cost of €473 (NordDRG
system Diagnosis Related Group, DRG 236: fracture in hip
or pelvis), €706 (traumatology treatment unit), and €1077
(DRG 211: surgery of hip or femur, adult, non-compli-
cated) for each hospital day were used [11, 12]. The total
healthcare cost of 27 scenarios was calculated. Also, the
cost of two different PCC preparations (PCC1: Cofact,
Sanquin, Amsterdam, the Netherlands and PCC2: Octa-
plex, Octapharma AG, Lachen, Switzerland) were com-
pared in a sensitivity analysis.
2.6 Statistics
The analysis was performed using MS Excel 2010




It was estimated that, annually, 410 hip fracture patients
require warfarin reversal in Finland. According to the base
case results, the least costly treatment options for warfarin
Table 1 Warfarin reversal methods, dose regimens, prices, and incremental healthcare resource utilization rates applied in the base-case analysis
(initial INR 3.0, target INR B1.5, bodyweight 70 kg)
Treatment Strength Pack Price per packa Dose per dayb Resource utilization rate
Hospital days INR testing







0.9 mL/kg 0 1
PCC2d 500 IU 20 mL €350.00 1.6 mL/kg 0 1
Vitamin K 10 mg/mL 5 9 1 mL €7.78 1–3 mg 1 6c
Warfarin withdrawal 4 8c
FFP fresh frozen plasma, INR international normalized ratio, IU international unit, PCC1 prothrombin complex concentrate, Cofact, PCC2
prothrombin complex concentrate, Octaplex
a Finnish drug database, wholesale prices 6.2.2014, excluding value added tax
b According to summaries of product characteristics (SPCs)
c Unit cost of INR testing (€8.63) is included in hospital day costs [10, 12]
d 50/50 share of two preparations in current treatment mix estimation
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reversal were vitamin K and PCC, which accounted for
€289,000 and €428,000 direct healthcare costs, respec-
tively (Fig. 1). The cost of vitamin K treatment depended
on incremental inpatient days, whereas PCC-based treat-
ment encompassed drug costs. The drug costs of PCC were
partly offset by the reduced healthcare resource use. The
most costly treatment, warfarin cessation, cost €1,157,000.
In the sensitivity analyses of 27 scenarios, vitamin K
and PCC were the least costly treatment options in 70 and
30 % of the scenarios, respectively (Table 2). In the same
analyses, PCC, vitamin K, and FFP were ranked as the
second least costly in 44, 30, and 26 % of the scenarios,
respectively. Furthermore, warfarin cessation was the most
costly treatment option in all scenarios.
3.2 Budget Impact Analysis
To estimate the budget impact of the treatments, informa-
tion on the current clinical practice was utilized to provide
a baseline against which the alternative treatment scenarios
were compared (Fig. 1). The proportion of each of the
warfarin reversal treatment options that are used in current
clinical practice was estimated based on the study ques-
tionnaire. The survey response rate among the chief anes-
thetists (N = 27) was 96 %. According to the survey, for
patients with a high INR ratio, vitamin K would be ad-
ministered for warfarin reversal in 20 of the 26 hospitals,
PCC in 19 of the 26 hospitals, and FFP in 7 of the 26
hospitals. The combination of PCC and vitamin K would
be the most common approach, followed by PCC, vitamin
K, and triple therapy (PCC–FFP–vitamin K). Single ther-
apy with FFP would be used in two hospitals, and FFP with
vitamin K would be used in one hospital. Based on the
survey, the current clinical practice of 37 % (PCC1), 37 %
(PCC2), 12 % (FFP), 15 % (vitamin K), and 0 % (warfarin
withdrawal) were assumed to depict the average clinical
practice in Finland. The transition from current practice to
a 100 % share of vitamin K, PCC1, or FFP would result in
a negative budget impact (i.e., cost savings). However, the
transition to warfarin withdrawal would result in extra
annual healthcare costs.
Alternatively, if a 100 % market share of each indi-
vidual treatment option was assumed, the comparison be-
tween PCC and the other reversal options indicated that the
Fig. 1 Total costs of different warfarin reversal treatment options in
hip fracture patients (n = 410) in Finland, base-case analysis (Initial
INR 3.0; bodyweight 70 kg, target INR B1.5, incremental hospital
day €706). Individual treatments represent 100 % treatment share.
Current treatment mix takes into account the current situation
according to a survey and 50/50 share of two PCC preparations.
FFP fresh frozen plasma, INR international normalized ratio, PCC
prothrombin complex concentrate
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Table 2 Total costs (9€1000)
of different warfarin reversal
treatment options in hip fracture
patients (n = 410) in Finland,
one- and two-way sensitivity
analysis (target INR B1.5)
DRG 211 surgery of hip or
femur, adult, not complicated,
DRG 236 fracture in hip or





a Incremental hospital day:
traumatology unit (€706); DRG
236 (€473); DRG 211 (€1077)
b Includes bridging therapy
c Base case: initial INR 3.0;
Bodyweight 70 kg;
Traumatology unit
d PCC1 denotes for Cofact
and PCC2 for Octaplex
Treatment Bodyweight (kg) Inital INR Incremental hospital day costa
INR 2.5 INR 3 INR 3.5
(9€1000)
Vitamin Kb 60 194 194 194 DRG 236
289 289 289 Traumatology unit
441 441 441 DRG 211
70 194 194 194 DRG 236
289 289c 289 Traumatology unit
441 441 441 DRG 211
80 194 194 194 DRG 236
289 289 289 Traumatology unit
441 441 441 DRG 211
PCC1d 60 286 357 428 DRG 236
286 357 428 Traumatology unit
286 357 428 DRG 211
70 286 428 498 DRG 236
286 428c 498 Traumatology unit
286 428 498 DRG 211
80 357 569 640 DRG 236
357 569 640 Traumatology unit
357 569 640 DRG 211
FFP 60 382 382 382 DRG 236
478 478 478 Traumatology unit
630 630 630 DRG 211
70 420 420 420 DRG 236
515 515c 515 Traumatology unit
667 667 667 DRG 211
80 420 420 420 DRG 236
515 515 515 Traumatology unit
667 667 667 DRG 211
PCC2d 60 577 720 864 DRG 236
577 720 864 Traumatology unit
577 720 864 DRG 211
70 720 864 864 DRG 236
720 864 864 Traumatology unit
720 864 864 DRG 211
80 864 864 864 DRG 236
864 864 864 Traumatology unit
864 864 864 DRG 211
Warfarin withdrawalb 60 776 776 776 DRG 236
1157 1157 1157 Traumatology unit
1765 1765 1765 DRG 211
70 776 776 776 DRG 236
1157 1157c 1157 Traumatology unit
1765 1765 1765 DRG 211
80 776 776 776 DRG 236
1157 1157 1157 Traumatology unit
1765 1765 1765 DRG 211
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total healthcare costs of PCC treatment would be higher
(?€139,000) compared with vitamin K (Fig. 1). However,
the budget impact of PCC would be cost-saving
(–€729,000, and –€87,000) compared with warfarin with-
drawal and FFP, respectively.
4 Discussion
The present cost analysis of warfarin reversal therapies
indicated that vitamin K and PCC were the least costly
warfarin reversal treatment options if direct healthcare
costs during hospitalization prior to the hip fracture surgery
were considered. Vitamin K induced costs solely because
of resource utilization due to operation delay, whereas PCC
prompted extra drug costs. However, the drug costs of PCC
were partly offset by savings in resource utilization, as the
operation delay was avoided. According to the budget
impact analysis, vitamin K, PCC, and FFP were profitable
if the current treatment mix was replaced by a 100 %
market share of each individual treatment option. However,
different safety profiles and contraindications may affect
the clinical implementation of treatment options, which
cannot be defined in monetary terms. The present budget
impact analysis was applied to the Finnish healthcare
system. Utilization of local cost and resource use data is a
relevant approach in economic evaluations. However, this
may affect the generalizability of the results across regions.
Potential bias arising from uncertainty in cost estimates
was reduced by using two extremes of hip fracture treat-
ment costs (DRG 211 and DRG 236) in the sensitivity
analyses.
Most patients with hip fractures are frail and have co-
morbidities. Operation delays lengthen the hospital stay
and may increase mortality [13–15]. Early surgery reduces
mortality; therefore, the current guidelines recommend
surgery during the first 36–48 h after the hip fracture [5].
One reason that an operation may be delayed is the pa-
tient’s use of oral anticoagulants. The action of these an-
ticoagulants should be reversed prior to the surgery to
establish appropriate hemostatic function and to optimize
the choice of anesthesia. The temporary withholding of
warfarin is not feasible in emergency surgery, as it may
take up to 5 days to establish appropriate hemostatic
function. Proper reversal strategies include the adminis-
tration of vitamin K, FFP, or a four-factor PCC, and the
choice of treatment method depends on the urgency of the
anticoagulant effect reversal [7, 8]. The various approaches
may have significant budget impacts. Furthermore, in
contrast to elective surgery, it is not consistently possible to
predict when an emergency care patient can be admitted to
surgery. Therefore, the system must be flexible so that the
surgery can be performed in a timely manner.
The cost analysis favored vitamin K as an anticoagula-
tion reversal therapy. The spontaneous reversal of antico-
agulation by temporary warfarin cessation takes several
days. As warfarin acts as a vitamin K antagonist, the re-
versal of anticoagulation is achieved more rapidly with the
concomitant administration of oral vitamin K [7, 16, 17]. If
1 mg of oral vitamin K is given 24 h before surgery, an
INR ratio can be normalized in some patients and corre-
lates with short duration of bridging therapy [18]. How-
ever, one-third of patients fail to respond to these lower
doses [19]. Intravenous vitamin K produces a more prompt
and complete reduction in the INR ratio than does oral or
subcutaneous vitamin K [7, 20–22]. If 3 mg of intravenous
vitamin K is administered in addition to the withholding of
warfarin, appropriate hemostatic function can be restored
within 24 h in 90 % of patients [9]. However, the desired
ratio is not achieved in all patients. Vitamin K is less ef-
fective in patients with supratherapeutic INR ratios, and
patients who receive vitamin K should have normal liver
function to synthesize and activate vitamin K-dependent
clotting factors. Moreover, after vitamin K administration
it may take 2–11 days to re-establish a therapeutic INR
ratio [9]. Therefore, patients may require bridging therapy
with LMWH and repeated INR testing for up to 2 weeks
after the surgery. Bridging therapy induces extra resource
utilization and costs. Therefore, vitamin K administration
is not an optimal approach in hip fracture surgery.
The cost analysis also favored PCC. The anticoagulant
effect of warfarin is mediated by the reduced coagulant
activity of four vitamin K-dependent clotting factors, II,
VII, IX, and X [7]. Prothrombin complex concentrates are
categorized as three- and four-factor products. Three-factor
products contain low concentrations of factor VII, whereas
four-factor PCCs contain factors II, VII, IX, and X and
proteins C and S. Therefore, four-factor PCCs are highly
effective in correcting INR ratios as soon as they are in
circulation [7]. With PCCs, a blood type definition is not
required. Furthermore, they are virally inactivated and can
be administered as a short-term infusion with no risk of
volume overload [7].
FFP products are indicated for the rapid reversal of the
effects of oral anticoagulants if vitamin K is insufficient
because of impaired liver function or in emergency situa-
tions. However, PCCs reverse anticoagulation more rapidly
and effectively and have a better safety profile than FFP
[23–26]. Additionally, the therapeutic volume of PCC is
1–2 mL/kg, whereas FFP is administered in volumes of
15 mL/kg or higher [26]. These higher volumes are asso-
ciated with an increased risk of volume overload; therefore,
prolonged infusion times are required [26, 27]. Although
FFP may be the treatment of choice in hypovolemic hip
fracture patients with a normal hematocrit value, in patients
with blood loss or anemia, large doses of FFP may impair
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hemostatic function by decreasing the hematocrit. More-
over, FFP may contain only 55–85 % of the physiological
concentrations of clotting factors [28]. Therefore, to ensure
that a patient is given, for example, 1000 IU of coagulation
factor IX, the infusion volume should be between 1200 and
1800 mL. If the generally accepted starting dose of 15 mL/
kg is given, a patient with a bodyweight of 70 kg may
receive only 600–900 IU of factor IX. This value is sig-
nificantly less than that of 1500 IU of 60 mL of PCC.
The various PCCs that are marketed in Finland have
different dosing guidelines (according to the summaries of
product characteristics [SPCs]), and different package
sizes, and hence different costs; therefore, two commercial
preparations were taken into account in the current treat-
ment mix. The recommended doses of PCC1 vary between
0.4 and 1.3 mL/kg depending on the initial INR, body-
weight, and target INR [29, 30]. The recommended doses
of PCC2 vary between 0.9 and 2.0 mL/kg (maximum dose
120 mL) [31]. Additionally, the availability of different
package sizes (PCC1) potentially decreases drug wastage
and thus decreases costs.
There are some limitations in the present study. Firstly,
the budget impact analysis is based on the Finnish price
level. Thus, the results should be interpreted with caution
in other regions. Secondly, in respect of the treatment
protocols, the study is based on a survey with a limited
number of local anesthesiologists. Nevertheless, the budget
impact analyses are according to dosages arising from
summaries of product characteristics. Despite the limita-
tions, the results provide a reasonable estimate of the local
clinical situation. Also, in order to take into account the
variation in dosage regimen, the sensitivity analyses were
applied for various bodyweights and initial INR values.
New oral anticoagulants, apixaban, dabigatran and ri-
varoxaban, have recently been approved as an alternative
for warfarin in some indications such as in patients with
non-valvular atrial fibrillation. One of the limitations of
these new compounds is that there are no specific antidotes
for any of these new compounds. It is recommended to
defer procedures that carry a risk for major bleeding or
bleeding into a close compartment until at least 24–48 h
after the last dose. However, no guidelines or strategies for
the reversal of the anticoagulant effects of these com-
pounds have ever been evaluated in clinical settings. Thus,
no recommendation on how to handle hip fracture patients
taking new oral anticoagulants can be given at this time
[32].
5 Conclusion
In conclusion, the four reversal strategies (i.e., the tempo-
rary withholding of warfarin, administration of vitamin K,
FFP, or a four-factor PCC) have different times of onset,
which substantially impact the surgical operation delay and
healthcare costs. Economic evaluations are performed to
help decision makers allocate scarce resources effectively,
and budget impact analysis is employed to evaluate the
consequences of the implementation of new treatments in
practice. The present budget impact analysis indicated that
a low dose of vitamin K and PCC are the most economical
options for warfarin reversal. This result should be con-
sidered in decision making and clinical practice.
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